Cargando…
Small-molecule PIK-93 modulates the tumor microenvironment to improve immune checkpoint blockade response
Immune checkpoint inhibitors (ICIs) targeting PD-L1 immunotherapy are state-of-the-art treatments for advanced non–small cell lung cancer (NSCLC). However, the treatment response of certain patients with NSCLC is unsatisfactory because of an unfavorable tumor microenvironment (TME) and poor permeabi...
Autores principales: | Lin, Chia-Yi, Huang, Kuo-Yen, Kao, Shih-Han, Lin, Ming-Shiu, Lin, Chih-Chien, Yang, Shuenn-Chen, Chung, Wei-Chia, Chang, Ya-Hsuan, Chein, Rong-Jie, Yang, Pan-Chyr |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for the Advancement of Science
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10081850/ https://www.ncbi.nlm.nih.gov/pubmed/37027467 http://dx.doi.org/10.1126/sciadv.ade9944 |
Ejemplares similares
-
Spatially targeted brain cancer immunotherapy with closed-loop controlled focused ultrasound and immune checkpoint blockade
por: Lee, Hohyun, et al.
Publicado: (2022) -
Loss of TSC1/TSC2 sensitizes immune
checkpoint blockade in non–small cell lung cancer
por: Huang, Qingyuan, et al.
Publicado: (2022) -
Synthetic enforcement of STING signaling in cancer cells appropriates the immune microenvironment for checkpoint inhibitor therapy
por: Vornholz, Larsen, et al.
Publicado: (2023) -
Antimetabolite pemetrexed primes a favorable tumor microenvironment for immune checkpoint blockade therapy
por: Lu, Chia-Sing, et al.
Publicado: (2020) -
Regulation of autoimmune disease progression by Pik3ip1 through metabolic reprogramming in T cells and therapeutic implications
por: Xie, Wenqiang, et al.
Publicado: (2022)